Results 71 to 80 of about 6,399,825 (302)

Interaction of human heat shock protein 70 with tumor-associated peptides [PDF]

open access: yes, 2009
Molecular chaperones of the heat shock protein 70 (Hsp70) family play a crucial role in the presentation of exogenous antigenic peptides by antigen-presenting cells (APCs).
Manzenrieder, Florian   +20 more
core   +1 more source

Engineering Antigen Density on M13 Bacteriophage for Personalized Nanovaccine

open access: yesAdvanced Healthcare Materials, EarlyView.
Increasing antigen density on the phage capsid impacts phage uptake and antigen cross‐presentation by antigen‐presenting cells, leading to enhanced activation of antitumor CD8+ T cells in the draining lymph nodes. These activated CD8+ T cells subsequently recognize the antigen‐expressing tumors and mediate their specific cytotoxic killing, thereby ...
Shengnan Huang   +7 more
wiley   +1 more source

Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine.

open access: yes, 2006
The immunogenicity and reactogenicity, in British schoolchildren, of the newly introduced Danish-SSI 1331 BCG vaccine was compared with that of the previously used Glaxo-Evans 1077 BCG vaccine. Interferon-gamma (IFN-gamma) response to M.
Fine, Paul EM   +11 more
core   +1 more source

Charge‐Reversed Lipid Nanoparticles Enable Encapsulation of Pt2L4 Nanocages for In vivo Anti‐Cancer Treatment

open access: yesAdvanced Materials, EarlyView.
Charge‐reversed lipid nanoparticles (revLNPs) enable efficient encapsulation and delivery of cationic Pt2L4 nanocages. Encapsulation preserves potent anticancer activity while improving circulation, reducing vascular leakage, and promoting favorable biodistribution in vivo.
Renzo A. Knol   +16 more
wiley   +1 more source

Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure

open access: yesCell Reports Medicine
Summary: The effectiveness of whole tumor cell vaccines prepared by traditional inactivation methodology is often hindered by insufficient immunogenicity.
Cheng Gao   +7 more
doaj   +1 more source

Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to ΔVP8* protein from rotavirus

open access: yes, 2021
Conjugation of carbohydrate antigens with a carrier protein is a clinically proven strategy to overcome the poor immunogenicity of bacterial polysaccharide.
조상래   +8 more
core   +1 more source

Biomass DNA: An Emerging Building Block for Advanced Materials

open access: yesAdvanced Materials, EarlyView.
Biomass DNA is rapidly emerging from its traditional role as a genetic blueprint to serve as a versatile abundant, highly programmable polymeric building block. This review highlights the transformation of macroscopic bulk biomass DNA into next generation of functional materials, spanning from dynamic hydrogels, sustainable bioplastics, and high ...
Yuwei Hu, Itamar Willner, Li Niu
wiley   +1 more source

The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant [PDF]

open access: yes, 2013
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials.
Cevayir Coban   +35 more
core   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer

open access: yesVaccines, 2020
Immune checkpoint inhibitor (ICI) immunotherapy improved the survival of head and neck squamous cell carcinoma (HNSCC) patients. However, more than 80% of the patients are still resistant to this therapy.
Ramireddy Bommireddy   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy